learningcurve2020
3 years ago
Bravo!!! So long Kriegsman!
CytRx Corporation (OTCQB:CYTR) ("CytRx" or the "Company"), a specialized biopharmaceutical company focused on research and development in oncology and neurodegenerative diseases, today announced that it has appointed Dr. Stephen Snowdy to the role of Chief Executive Officer, effective January 10, 2022. Dr. Louis Ignarro succeeded Steven A. Kriegsman as Chairman of the Board of Directors (the "Board") on January 3, 2022.
Dr. Snowdy is a scientist, serial entrepreneur and medical venture capitalist with two decades of experience in life science investing and executive management.
john sezso
4 years ago
Mr. Caloz has entered into a new employment agreement which would tend to predict another years employment with CYTR.
>>>On January 5, 2021, CytRx Corporation (โthe Companyโ) entered into a new Employment Agreement, effective January 1, 2021, with John Y. Caloz, under which we agree to continue to employ Mr. Caloz as our Chief Financial Officer through December 31, 2021<<<
john sezso
4 years ago
For the newly curious about CYTR:
CytRx Corporation (OTCQB: CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics principally to treat patients with cancer and neurodegenerative diseases. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been outlicensed to ImmunityBio, Inc. In addition, CytRx's other drug candidate, arimoclomol, was sold to Orphazyme (Nasdaq: ORPH) Orphazyme A/S (Nasdaq Copenhagen exchange: ORPHA.CO) in exchange for milestone payments and royalties. Orphazyme is testing arimoclomol in four indications including amyotrophic lateral sclerosis (ALS), Niemann-Pick disease Type C (NPC), Gaucher disease and sporadic Inclusion Body Myositis (sIBM). CytRx Corporationโs website is www.cytrx.com.